FDA ‘fast-tracks’ Valley fever treatment

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VT-1598, a novel oral agent for the treatment of coccidioidomycosis, also known as Valley Fever, according to Viamet Pharmaceuticals last week. VT-1598 is an orally available inhibitor of fungal CYP51 that has demonstrated high potency against a broad range of fungal pathogens, including ["]

The post FDA 'fast-tracks' Valley fever treatment appeared first on Outbreak News Today.